Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339115 | PMC |
| http://dx.doi.org/10.5826/dpc.1503a5420 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cutaneous neuroanatomical and cellular response to dupilumab treatment in atopic dermatitis.
J Invest Dermatol
August 2025
Department of Dermatology, Section Pruritus Medicine and Center for Chronic Pruritus, University Hospital Muenster, Muenster, Germany. Electronic address:
Itch is the dominant symptom in atopic dermatitis (AD). Cutaneous neuronal alterations underlying this symptom are still poorly understood. Therefore, we aimed at deciphering cutaneous neuronal alterations during AD treatment with dupilumab.
View Article and Find Full Text PDFDecreased Risk of Reduced Linear Growth Among Children with Atopic Dermatitis Receiving Dupilumab: A Cohort Study.
J Am Acad Dermatol
August 2025
Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chao Tung University, Taipei, Taiwan; Institute of Public Health and Department of Public Health, National Yang Ming Chiao Tung University, Taipei, Taiwan; National Yang Ming Chiao Tun
Background: Existing studies have shown inconsistent results regarding the association between atopic dermatitis (AD) and linear growth, and the relationship between dupilumab use and height remains unclear.
Objective: This study examines the association between AD and reduced stature in children and evaluates the influence of dupilumab on growth outcomes in real-world clinical settings.
Methods: Utilizing the TriNetX US Collaborative Network, we conducted a retrospective cohort study from January 2018 to December 2023 involving children aged <18 years.
The Role of Dupilumab in Atopic Dermatitis-Like Graft-Versus-Host Disease.
Cureus
July 2025
Pediatric Allergology Unit, Centro Materno Infantil do Norte, Unidade Local de Saúde de Santo António, Porto, PRT.
Atopic dermatitis-like graft-versus-host disease (AD-like GVHD) is a rare but challenging complication following hematopoietic stem cell transplantation (HSCT), mimicking features of atopic dermatitis (AD) and often requiring prolonged immunosuppression. We report the case of a 14-year-old girl with a history of mild AD and post-HSCT GVHD involving skin and the gastrointestinal tract, presenting with severe pruritus, extensive eczema, and significant impact on quality of life. Standard treatment with corticosteroids and immunosuppressants yielded suboptimal results and notable side effects, including growth retardation.
View Article and Find Full Text PDFThe Effect of Dupilumab on Growth Parameters in Pediatric Atopic Dermatitis Patients.
Dermatol Pract Concept
July 2025
Division of Dermatology, Azienda USL Toscana Nord Ovest, Lucca, Italy.
Successful management of Netherton syndrome using IVIG and dupilumab: A case report.
J Allergy Clin Immunol Glob
August 2025
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Netherton syndrome (NS) is a rare autosomal recessive genodermatosis caused by pathogenic mutations in the serine protease inhibitor Kazal-type 5 () gene, leading to impaired skin barrier function and immune dysregulation. It is characterized by congenital ichthyosis, trichorrhexis invaginata, and severe atopy. Herein, we present the case of a young boy with NS, confirmed by genetic analysis revealing a homozygous splice site mutation in (c.
View Article and Find Full Text PDF